FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “BeyondSpring Surged 191% Following Positive Topline Results from its DUBLIN-3 Registrational Trial”
BeyondSpring (NASDAQ: BYSI) skyrocketed over 191% in premarket trading after the company announced the positive topline data from the DUBLIN-3 registrational trial.
The study met primary and secondary endpoints, showing statistically significant improvement in overall survival and statistically significant improvement for the combination of plinabulin with docetaxel against docetaxel alone in ORR, PFS, and 24- and 36-month OS rates.
Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset plinabulin, is being developed as a “pipeline in a drug.” It is filed for approval and has received Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) with a PDUFA date of November 30, 2021 in the U.S., and has a fully enrolled pivotal study (DUBLIN-3) to test an anti-cancer benefit with an overall survival primary endpoint in NSCLC. Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the effects of PD-1 / PD-L1 antibodies.
For more information, please visit: BeyondSpring
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.